HAYA Therapeutics Advances First-in-Class RNA Therapy Into Phase 1 Trial for Cardiac Fibrosis
According to a recent article on PharmaBiz, HAYA Therapeutics has announced the completion of dosing in the first cohort of its phase 1 clinical study evaluating HTX-001, an investigational RNA-targeting…
Continue Reading
HAYA Therapeutics Advances First-in-Class RNA Therapy Into Phase 1 Trial for Cardiac Fibrosis
